New MGA Report on the Potential Savings from Accelerating US Approval of Complex Generics

Matrix Global Advisors (MGA) today released a new report, “Potential Savings from Accelerating US Approval of Complex Generics,” by MGA founder and CEO Alex Brill. The report looks at the important but underutilized avenue of savings for US patients and healthcare payors represented by complex generics, and includes analysis of the efforts to promote the approval of complex generics, as well as the slow approval process by the US Food and Drug Administration (FDA).

For a PDF of the full report, click here.
For a summary of the report, click here.